Compare Abbott Laboratories (ABT) vs Msci Inc (MSCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Msci Inc — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while Msci Inc trades at $602.12 (market cap $44.27B). The key difference: Abbott Laboratories is far larger — about 3.8× Msci Inc's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | MSCI | |
|---|---|---|
Market Cap | $166.94B | $44.27B |
Sector | Health | Financials |
52-Week High | $136.62 | $643.83 |
52-Week Low | $82.57 | $511.84 |
Enterprise Value | $193.69B | $50.43B |
Dividend Yield | 2.63% | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
MSCI trades at $608.09, up 0.83% with a bullish technical outlook and strong fundamental performance. The company delivered three consecutive quarterly earnings beats, maintains exceptional profit margins above 40%, and shows consistent revenue growth. Recent strategic acquisitions and AI integration initiatives position MSCI for continued market leadership in financial analytics and index services.
With 69% analyst buy ratings and a $700.50 consensus price target representing 15% upside, MSCI offers growth potential despite premium valuations. Key risks include high debt levels and market classification decisions impacting revenue streams. The stock's current technical setup near pivot point $606 suggests potential for continued upward momentum if earnings momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
